Comment
Outbreak of multidrug-resistant tuberculosis on Daru Island

https://doi.org/10.1016/S2213-2600(16)00101-6Get rights and content

First page preview

First page preview
Click to open first page preview

References (15)

There are more references available in the full text version of this article.

Cited by (18)

  • Ebola Virus Epidemic in West Africa: Global Health Economic Challenges, Lessons Learned, and Policy Recommendations

    2017, Value in Health Regional Issues
    Citation Excerpt :

    We examine the response to the latest EVD outbreak in West Africa, identify direct and indirect treatment costs to treat the patient from a public health system perspective, present key economic challenges and lessons learned, and highlight policy recommendations to further assist an already stretched health system in Africa. There were institutional failures of some international organizations that had grave consequences for global health in Sri Lanka in 2009, Haiti in 2010, South Sudan in 2013, and the multidrug-resistant tuberculosis response in Papua New Guinea at present [5,6]. It is important to reconsider how the global health architecture should be reshaped to allow for greater assurance of global health and to prevent future health crises.

  • The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains

    2017, International Journal of Infectious Diseases
    Citation Excerpt :

    In contrast, the highest proportions of isolates showing drug resistance are found in Eastern Europe, with 32% and 76% of new and previously treated cases, respectively, found to be MDR-TB in Belarus.29 However, the true global incidence of MDR-TB is unknown, the proportion of new cases tested for drug susceptibility is only 12% globally,1 and MDR-TB is spreading in countries with the poorest surveillance systems; for example, the incidence of MDR-TB may be as high as 1000 per 100 000 population in Daru, Papua New Guinea.30 On the basis of early evidence of the variable and slow emergence of multidrug resistance decades after the introduction of therapy, many argued that MDR-TB would not replace DS-TB.31

View all citing articles on Scopus
View full text